- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.02. | B.Riley reiterates Buy rating on Journey Medical stock, maintains $12 target | 2 | Investing.com | ||
| 08.01. | Journey Medical (DERM) Publishes Positive Emrosi Phase 1 Microbiome Data | 2 | Insider Monkey | ||
| 10.12.25 | Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology | 3 | GlobeNewswire (USA) | ||
| 12.11.25 | Earnings Call: Journey Medical meldet Umsatzwachstum für Q3 2025 und stellt positives EBITDA in Aussicht | 6 | Investing.com Deutsch | ||
| 12.11.25 | Journey Medical GAAP EPS of -$0.09, revenue of $17.6M | 2 | Seeking Alpha | ||
| 12.11.25 | Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 228 | GlobeNewswire (Europe) | Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today... ► Artikel lesen | |
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.11.25 | Insights into Journey Medical's Upcoming Earnings | 13 | Benzinga.com | ||
| 05.11.25 | Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 | 2 | GlobeNewswire (USA) | ||
| 24.10.25 | Journey Medical Reports Pooled Phase 3 Data For Emrosi In Rosacea | 2 | RTTNews | ||
| 24.10.25 | Journey Medical's Emrosi shows superior efficacy for rosacea | 1 | Investing.com | ||
| 26.09.25 | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 22.09.25 | Summers Value Partners' Update on Journey Medical (DERM) | 6 | Insider Monkey | ||
| 12.08.25 | Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 615 | GlobeNewswire (Europe) | Second quarter 2025 revenues were $15.0 million Emrosi net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June... ► Artikel lesen | |
| 14.05.25 | Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | 161 | GlobeNewswire (Europe) |
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions... ► Artikel lesen | |
| 01.04.25 | Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer | 240 | GlobeNewswire (Europe) | SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses... ► Artikel lesen | |
| 26.03.25 | Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights | 703 | GlobeNewswire (Europe) | FDA Approval of Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,350 | -0,17 % | Pfizer, Astellas Pharma Share Positive Data From Bladder Cancer Trial | NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Astellas Pharma Inc., Friday announced the positive results from the Phase 3 EV-304 clinical trial for PADCEV in combination with Keytruda in... ► Artikel lesen | |
| GILEAD SCIENCES | 125,66 | -0,33 % | Gilead Sciences auf Einkaufstour: Wer folgt als Nächstes? | Gilead Sciences lässt seinen Worten Taten folgen: Mit einer ersten Multi-Milliarden-Übernahme im laufenden Jahr stärkt der Pharmakonzern seine Pipeline. Weiterhin ausstehend: eine bedeutende Transaktion... ► Artikel lesen | |
| ELI LILLY | 889,90 | -0,11 % | Rückschlag im Abnehm-Boom: Lilly schlägt Novo deutlich | Der globale Markt für Abnehmmedikamente wächst rasant - doch der Wettbewerb verschärft sich. Neue Studiendaten setzen einen der führenden Anbieter spürbar unter Druck. Für Anleger rückt damit die Frage... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 420,00 | -0,11 % | Vertex Pharmaceuticals Inc. Reports Rise In Q4 Bottom Line | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) reported earnings for its fourth quarter that Increases, from last yearThe company's earnings came in at $1.191 billion... ► Artikel lesen | |
| EYEPOINT | 14,670 | 0,00 % | EyePoint Pharmaceuticals, Inc.: EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 | ||
| LIGAND PHARMACEUTICALS | 166,00 | +9,21 % | Expert Outlook: Ligand Pharmaceuticals Through The Eyes Of 5 Analysts | ||
| JAZZ PHARMACEUTICALS | 159,55 | -0,78 % | Jazz Pharmaceuticals Plc Q4 Profit Climbs | WASHINGTON (dpa-AFX) - Jazz Pharmaceuticals plc (JAZZ) released earnings for its fourth quarter that Increases, from the same period last yearThe company's earnings totaled $203.45 million,... ► Artikel lesen | |
| OPKO HEALTH | 1,020 | 0,00 % | OPKO Health, Inc.: OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results | MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces... ► Artikel lesen | |
| UNITED THERAPEUTICS | 426,00 | -0,02 % | H.C. Wainwright Raises United Therapeutics (UTHR) Target to $600 | ||
| ROYALTY PHARMA | 39,000 | -0,28 % | Royalty Pharma: TD Cowen hebt Kursziel wegen Wachstumsaussichten auf 50 $ an | ||
| CATALYST PHARMACEUTICALS | 19,425 | -0,49 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3%... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 55,90 | -0,64 % | BridgeBio Pharma, Inc.: BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates | $154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectivelyBridgeBio... ► Artikel lesen | |
| TG THERAPEUTICS | 25,700 | +0,92 % | TG Therapeutics, Inc.: TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance | Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approximately... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 6,950 | -4,14 % | Corbus Pharmaceuticals Holdings, Inc. - 8-K, Current Report | ||
| SOLIGENIX | 1,180 | +2,61 % | Soligenix Gets Positive EMA Opinion For Orphan Drug Status Of SGX945 |
JOURNEY MEDICAL CORPORATION gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,580 (-6,66 %) liegt der Kurs bei 8,130 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.